This month, the Department of Health and Human Services terminated almost $500 million in mRNA vaccine development grants and contracts. 

While HHS has said that these cuts won’t affect mRNA cancer research, some researchers have expressed concern about the impact on their ongoing work. In light of these developments, we’re revisiting a conversation from February.

A team at Memorial Sloan Kettering is developing an mRNA vaccine for pancreatic cancer, which is notoriously difficult to treat. A few years ago, 

the team embarked on a small trial to test the vaccine’s safety. Sixteen patients with pancreatic cancer received it, and half of them had a strong immune response. A follow-up study found that in six of those patients, the cancer hadn’t relapsed after three years.

Host Flora Lichtman spoke to study author Vinod Balachandran about the work, which has not yet been affected by the cuts, according to Memorial Sloan Kettering.

Source: sciencefriday